Endocrine Abstracts

Background: Tyrosine Kinase Inhibitors show great promise in the management of metastatic Medullary Thyroid Carcinoma.Somatic mutations are considered to play a major role in the response/resistance to therapies.RET-somatic mutations are present in 45-75% of sporadic MTCs while RAS are rarer.Objectives: The aim of this study is to investigate the mutational profile of 18 spMTC pts, with metastatic/biochemical persistent disease and to look into possible ...